Nervgen Pharma Corp Stock Performance

NGENF Stock  USD 4.16  0.11  2.72%   
On a scale of 0 to 100, NervGen Pharma holds a performance score of 11. The company secures a Beta (Market Risk) of 2.57, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NervGen Pharma will likely underperform. Please check NervGen Pharma's expected short fall, and the relationship between the value at risk and daily balance of power , to make a quick decision on whether NervGen Pharma's current price movements will revert.

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in NervGen Pharma Corp are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, NervGen Pharma reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Begin Period Cash Flow5.6 M
Total Cashflows From Investing Activities-45.1 K
  

NervGen Pharma Relative Risk vs. Return Landscape

If you would invest  284.00  in NervGen Pharma Corp on November 21, 2025 and sell it today you would earn a total of  132.00  from holding NervGen Pharma Corp or generate 46.48% return on investment over 90 days. NervGen Pharma Corp is currently producing 0.782% returns and takes up 5.3421% volatility of returns over 90 trading days. Put another way, 47% of traded otc stocks are less volatile than NervGen, and 85% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon NervGen Pharma is expected to generate 7.15 times more return on investment than the market. However, the company is 7.15 times more volatile than its market benchmark. It trades about 0.15 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.17 per unit of risk.

NervGen Pharma Target Price Odds to finish over Current Price

The tendency of NervGen OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 4.16 90 days 4.16 
about 59.47
Based on a normal probability distribution, the odds of NervGen Pharma to move above the current price in 90 days from now is about 59.47 (This NervGen Pharma Corp probability density function shows the probability of NervGen OTC Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon the otc stock has the beta coefficient of 2.57 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, NervGen Pharma will likely underperform. Additionally NervGen Pharma Corp has an alpha of 0.7099, implying that it can generate a 0.71 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   NervGen Pharma Price Density   
       Price  

Predictive Modules for NervGen Pharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as NervGen Pharma Corp. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.214.169.71
Details
Intrinsic
Valuation
LowRealHigh
0.214.209.75
Details
Naive
Forecast
LowNextHigh
0.105.0510.59
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.524.076.62
Details

NervGen Pharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. NervGen Pharma is not an exception. The market had few large corrections towards the NervGen Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold NervGen Pharma Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of NervGen Pharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.71
β
Beta against Dow Jones2.57
σ
Overall volatility
0.96
Ir
Information ratio 0.13

NervGen Pharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of NervGen Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for NervGen Pharma Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
NervGen Pharma Corp is way too risky over 90 days horizon
NervGen Pharma Corp appears to be risky and price may revert if volatility continues
NervGen Pharma Corp has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (12.73 M) with profit before overhead, payroll, taxes, and interest of 0.
NervGen Pharma Corp has accumulated about 11.65 M in cash with (8.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.2.
Roughly 25.0% of the company outstanding shares are owned by corporate insiders

NervGen Pharma Fundamentals Growth

NervGen OTC Stock prices reflect investors' perceptions of the future prospects and financial health of NervGen Pharma, and NervGen Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NervGen OTC Stock performance.

About NervGen Pharma Performance

By analyzing NervGen Pharma's fundamental ratios, stakeholders can gain valuable insights into NervGen Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if NervGen Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NervGen Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada. NERVGEN PHARMA operates under Biotechnology classification in the United States and is traded on OTC Exchange.

Things to note about NervGen Pharma Corp performance evaluation

Checking the ongoing alerts about NervGen Pharma for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for NervGen Pharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
NervGen Pharma Corp is way too risky over 90 days horizon
NervGen Pharma Corp appears to be risky and price may revert if volatility continues
NervGen Pharma Corp has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (12.73 M) with profit before overhead, payroll, taxes, and interest of 0.
NervGen Pharma Corp has accumulated about 11.65 M in cash with (8.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.2.
Roughly 25.0% of the company outstanding shares are owned by corporate insiders
Evaluating NervGen Pharma's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate NervGen Pharma's otc stock performance include:
  • Analyzing NervGen Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NervGen Pharma's stock is overvalued or undervalued compared to its peers.
  • Examining NervGen Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating NervGen Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NervGen Pharma's management team can help you assess the OTC Stock's leadership.
  • Pay attention to analyst opinions and ratings of NervGen Pharma's otc stock. These opinions can provide insight into NervGen Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating NervGen Pharma's otc stock performance is not an exact science, and many factors can impact NervGen Pharma's otc stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for NervGen OTC Stock analysis

When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity